Abstract
Rationale
To improve outcomes for patients undergoing extinction-based therapies (e.g., exposure therapy) for anxiety disorders such as post-traumatic stress disorder (PTSD), there has been interest in identifying pharmaceutical compounds that might facilitate fear extinction learning and recall. Oxytocin (OT) is a mammalian neuropeptide that modulates activation of fear extinction-based neural circuits and fear responses. Little is known, however, about the effects of OT treatment on conditioned fear responding and extinction in humans.
Objectives
The purpose of the present study was to assess the effects of OT in a fear-potentiated startle task of fear conditioning and extinction.
Methods
A double-blind, placebo-controlled study of 44 healthy human participants was conducted. Participants underwent a conditioned fear acquisition procedure, after which they were randomized to treatment group and delivered OT (24 IU) or placebo via intranasal (IN) spray. Forty-five minutes after treatment, participants underwent extinction training. Twenty-four hours later, subjects were tested for extinction recall.
Results
Relative to placebo, the OT group showed increased fear-potentiated startle responding during the earliest stage of extinction training relative to placebo; however, all treatment groups showed the same level of reduced responding by the end of extinction training. Twenty-four hours later, the OT group showed significantly higher recall of extinction relative to placebo.
Conclusions
The current study provides preliminary evidence that OT may facilitate fear extinction recall in humans. These results support further study of OT as a potential adjunctive treatment for extinction-based therapies in fear-related disorders.
Similar content being viewed by others
References
Acheson DT, Stein MB, Paulus MP, Geyer MA, Risbrough VB (2012) The effect of pregabalin on sensory motor gating in ‘low’ gating humans and mice. Neuropharmacology 63:480–485
Acheson DT, Gresack J, Risbrough VB (2011) Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology 62:674–685
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, Girolamo G, Graaf R, Demyttenaere K et al (2004) Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 109:21–27
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (fourth edition, text revision). Washington, DC
Bartels A (2012) Oxytocin and the social brain: beware the complexity. Neuropsychopharmacology 37:1795–1796
Baumgartner T, Heinrichs M, Vonlathen A, Fischbacher U, Fehr E (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58:639–650
Bradley R, Greene J, Russ E, Dutra L, Westen D (2005) A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry 162:214–227
Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis CG, Andreski P (1998) Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry 55:626–632
Cloitre M (2009) Effective psychotherapies for posttraumatic stress disorder: a review and critique. CNS Spectrum 14:32–43
Committee on Treatment of Posttraumatic Stress Disorder IoMotNA (2007) Treatment of posttraumatic stress disorder: an assessment of the evidence. The National Academies Press, Washington, DC
de Kleine RA, Hendriks G, Kusters WJC, Broekman TG, van Minnen A (2012) A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry
de Oliveira DC, Chagas MH, Garcia LV, Crippa JA, Zuardi AW (2012) Oxytocin interference in the effects induced by inhalation of 7.5 % CO(2) in healthy volunteers. Hum Psychopharmacol 27(4):378–385
Domes G, Heinrichs M, Glascher J, Buchel C, Braus DF, Herpertz SC (2007) Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 62:1187–1190
Druss BG, Hwang I, Petukhova M, Sampson NA, Wang PS, Kessler RC (2008) Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication. Mol Psychiatry 14:728–737
Etkin A, Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164:1476–1488
Feifel D (2012) Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 37:304–305
Foa EB, Rothbaum BO (1998) Treating the trauma of rape: cognitive–behavioral therapy for PTSD. Guilford, New York
Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS (2009) A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34:917–923
Grillon C, Krimsky M, Charney DR, Vytal K, Ernst M, Cornwell B (2012) Oxytocin increases anxiety to unpredictable threat. Mol Psychiatry. doi:10.1038/mp.2012.156
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U (2003) Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54:1389–1398
Heinrichs M, Meinlschmidt G, Wippich W, Ehlert U, Hellhammer DH (2004) Selective amnesic effects of oxytocin on human memory. Physiol Behav 83(1):31–38
Hembree EA, Foa EB, Dorfan NM, Street GP, Kowalski J, Tu X (2003) Do patients drop out prematurely from exposure therapy for PTSD? J Trauma Stress 16:555–562
Herzmann G, Young B, Bird CW, Curran T (2012) Oxytocin can impair memory for social and non-social visual objects: a within-subject investigation of oxytocin's effects on human memory. Brain Res 1451:65–73
Hodgson R, Rachman S (1974) II. Desynchrony in measures of fear. Behav Res Ther 12:319–326
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627
Kirsch P, Esslinger C, Chen Q et al (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25:11489–11493
LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA (1998) Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 20:937–945
Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, Stout JC, Nathan PJ (2010) Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 35(12):2403–2413
Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID (2011) The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 36(11):2159–2168
Milad MR, Quirk GJ (2012) Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol 63:129–151
Milad MR, Orr SP, Lasko NB, Chang Y, Rauch SL, Pitman RK (2008) Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res 42:515–520
Milad MR, Wright CL, Orr SP, Pitman RK, Quirk GJ, Rauch SL (2007) Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 62:446–454
Mueller D, Porter JT, Quirk GJ (2008) Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 28:369–375
Meyer-Lindengergy A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12:524–538
Myers KM, Davis M (2007) Mechanisms of fear extinction. Molecular Psychiatry 12:120–150
Ninan I (2011) Oxytocin suppresses basal glutamatergic transmission but facilitates activity-dependent synaptic potentiation in the medial prefrontal cortex. J Neurochem 119(2):324–331
Norberg MM, Krystal JH, Tolin D (2008) A meta-analysis of D-cycloserine and facilitation of fear extinction and exposure therapy. Biol Psychiatry 63:1118–1126
Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B, Ressler KJ (2011) Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 15:556–563
Norrholm SD, Jovanovic T, Vervliet B, Myers KM, Davis M, Rothbaum BO, Duncan EJ (2006) Conditioned fear extinction and reinstatement in a human fear-potentiated startle paradigm. Learn Mem 13:681–685
Olff M, Langeland W, Witteveen A, Denys D (2010) A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectrum 15:522–530
Petrovic P, Kalisch R, Singer T, Dolan RJ (2008) Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci 28:6607–6615
Phelps EA, Delgado MR, Nearing KI, LeDoux JE (2004) Extinction learning in humans: role of the amygdala and vmPFC. Neuron 43(6):897–905
Rescorla RA, Wagner AR (1972) A theory of Pavlovian conditioning: variations in the effectiveness of reinforcement and nonreinforcement. In: Black AH, Prokasy WF (eds) Classical Conditioning II. Appleton-Century-Crofts, p 64–99
Schnurr PP, Friendman MJ, Engel CC, Foa EB, Shea M, Chow BK et al (2007) Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. JAMA 297:820–830
Shin LM, Rauch SL, Pitman RK (2006) Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci 1071:67–79
Sripada CS, Phan KL, Labuschagne 2012 I, Welsh R, Nathan PJ, Wood AG (2012) Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. Int J Neuropsychopharmacol 30:1–6
Striepens N, Kendrick KM, Maier W, Hurlemann R (2011) Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 32(4):426–450
Toth I, Neumann ID, Slattery DA (2012) Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology
Acknowledgments
These studies were supported by the Veterans Affairs Center for Excellence in Stress and Mental Health (VB, JL), Defense Medical Research and Development Program award #DM102425 (VB, DA), R34 MH091285 (DF), and a Brain and Behavior Research Foundation (NARSAD) Young Investigator Award (DA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Acheson, D., Feifel, D., de Wilde, S. et al. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology 229, 199–208 (2013). https://doi.org/10.1007/s00213-013-3099-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-013-3099-4